Vanguard Personalized Indexing Management LLC Has $1.02 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Personalized Indexing Management LLC decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 9.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 5,735 shares of the biopharmaceutical company’s stock after selling 623 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,016,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $240,703,000. Capital International Investors lifted its holdings in Alnylam Pharmaceuticals by 29.2% during the 2nd quarter. Capital International Investors now owns 2,880,643 shares of the biopharmaceutical company’s stock worth $547,152,000 after purchasing an additional 651,054 shares during the last quarter. Eaton Vance Management grew its stake in shares of Alnylam Pharmaceuticals by 606.7% in the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after acquiring an additional 262,893 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Alnylam Pharmaceuticals by 39.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 775,596 shares of the biopharmaceutical company’s stock worth $147,317,000 after purchasing an additional 221,259 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Alnylam Pharmaceuticals by 328.9% during the 1st quarter. Ameriprise Financial Inc. now owns 203,170 shares of the biopharmaceutical company’s stock worth $40,699,000 after acquiring an additional 155,795 shares during the period. Institutional investors and hedge funds own 93.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ALNY. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $175.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Piper Sandler upped their target price on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an “overweight” rating in a research report on Thursday, December 14th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $230.95.

Read Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $170.03 on Monday. The firm has a market capitalization of $21.34 billion, a P/E ratio of -41.07 and a beta of 0.43. Alnylam Pharmaceuticals, Inc. has a 52 week low of $148.10 and a 52 week high of $227.91. The stock has a 50 day moving average price of $183.74 and a two-hundred day moving average price of $179.49.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 30,000 shares of the company’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the completion of the sale, the director now directly owns 16,029 shares of the company’s stock, valued at approximately $3,125,655. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Further Reading

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.